Esmée J Grobbee1, Eline H Schreuders1, Bettina E Hansen1, Marco J Bruno1, Iris Lansdorp-Vogelaar2, Manon C W Spaander3, Ernst J Kuipers1. 1. Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands. 2. Department of Public Health, Erasmus MC University Medical Centre, Rotterdam, The Netherlands. 3. Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands. Electronic address: v.spaander@erasmusmc.nl.
Abstract
BACKGROUND & AIMS: Colorectal cancer (CRC) screening using quantitative fecal immunochemical tests (FITs) is rapidly gaining ground worldwide. FITs are invariably used in a dichotomous manner using pre-specified cut-off values. To optimize FIT-based screening programs, we investigated the association between fecal hemoglobin (fHb) concentrations below the FIT cut-off value and later development of colorectal advanced neoplasia (AN). METHODS: We analyzed data collected from a population-based study of 9561 average-risk subjects (50-74 years old) in the Netherlands who were offered 4 rounds of FIT screening for CRC from November 2006 through December 2014. We analyzed data from 7663 participants screened at least once and found to have a negative FIT result at baseline (below the cut-off value of 10 μg Hb/ g feces). Participants were followed for a median of 4.7 years (interquartile range, 2.0-6.1 years); CRCs diagnosed outside the screening program were identified from the Dutch Comprehensive Cancer Centre database. Hazard ratios for AN were determined using Cox proportional hazard regression analyses. Logistic regression techniques were used to calculate risks of AN after consecutive fHb concentrations below the cut-off value. RESULTS: After 8 years of follow-up, participants with baseline concentrations of 8-10 μg fHb/g had a higher cumulative incidence of AN (33%) than participants with 0 μg fHb/g (5%) (P < .001). Multi-variate hazard ratios increased from 1.2 for subjects with concentrations of 0-2 μg fHb/g to 8.2 for subjects with concentrations of 8-10 μg fHb/g (P < .001). Participants with 2 consecutive fHb concentrations of 8 μg Hb/g had a 14-fold increase in risk of AN compared with participants with 2 consecutive fHb concentrations of 0 μg Hb/g (P < .001). CONCLUSIONS: In a population-based study of average-risk individuals with a FIT result below the cut-off value, we associated baseline concentrations of 8-10 μg fHb/g with an increased risk of AN compared with baseline concentrations of 0 μg fHb/g. Baseline and consecutive fHb concentrations are independent predictors for incident AN. This information might be used in designing personalized strategies for population-based CRC screening and reduce unnecessary repeat tests. Trialregister.nl no: first round, NTR1096; second round and additional invitees, NTR1512.
BACKGROUND & AIMS:Colorectal cancer (CRC) screening using quantitative fecal immunochemical tests (FITs) is rapidly gaining ground worldwide. FITs are invariably used in a dichotomous manner using pre-specified cut-off values. To optimize FIT-based screening programs, we investigated the association between fecal hemoglobin (fHb) concentrations below the FIT cut-off value and later development of colorectal advanced neoplasia (AN). METHODS: We analyzed data collected from a population-based study of 9561 average-risk subjects (50-74 years old) in the Netherlands who were offered 4 rounds of FIT screening for CRC from November 2006 through December 2014. We analyzed data from 7663 participants screened at least once and found to have a negative FIT result at baseline (below the cut-off value of 10 μg Hb/ g feces). Participants were followed for a median of 4.7 years (interquartile range, 2.0-6.1 years); CRCs diagnosed outside the screening program were identified from the Dutch Comprehensive Cancer Centre database. Hazard ratios for AN were determined using Cox proportional hazard regression analyses. Logistic regression techniques were used to calculate risks of AN after consecutive fHb concentrations below the cut-off value. RESULTS: After 8 years of follow-up, participants with baseline concentrations of 8-10 μg fHb/g had a higher cumulative incidence of AN (33%) than participants with 0 μg fHb/g (5%) (P < .001). Multi-variate hazard ratios increased from 1.2 for subjects with concentrations of 0-2 μg fHb/g to 8.2 for subjects with concentrations of 8-10 μg fHb/g (P < .001). Participants with 2 consecutive fHb concentrations of 8 μg Hb/g had a 14-fold increase in risk of AN compared with participants with 2 consecutive fHb concentrations of 0 μg Hb/g (P < .001). CONCLUSIONS: In a population-based study of average-risk individuals with a FIT result below the cut-off value, we associated baseline concentrations of 8-10 μg fHb/g with an increased risk of AN compared with baseline concentrations of 0 μg fHb/g. Baseline and consecutive fHb concentrations are independent predictors for incident AN. This information might be used in designing personalized strategies for population-based CRC screening and reduce unnecessary repeat tests. Trialregister.nl no: first round, NTR1096; second round and additional invitees, NTR1512.
Authors: Caitlin C Murphy; Ahana Sen; Bianca Watson; Samir Gupta; Helen Mayo; Amit G Singal Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-11-18 Impact factor: 4.254
Authors: Iris Lansdorp-Vogelaar; Reinier Meester; Lucie de Jonge; Andrea Buron; Ulrike Haug; Carlo Senore Journal: Int J Cancer Date: 2021-09-06 Impact factor: 7.316
Authors: Arthur I Kooyker; Esther Toes-Zoutendijk; Annemieke W J Opstal-van Winden; Manon C W Spaander; Maaike Buskermolen; Hanneke J van Vuuren; Ernst J Kuipers; Folkert J van Kemenade; Chris Ramakers; Maarten G J Thomeer; Evelien Dekker; Iris D Nagtegaal; Harry J de Koning; Monique E van Leerdam; Iris Lansdorp-Vogelaar Journal: Int J Cancer Date: 2020-01-09 Impact factor: 7.396
Authors: Luuk A van Duuren; Jonathan Ozik; Remy Spliet; Nicholson T Collier; Iris Lansdorp-Vogelaar; Reinier G S Meester Journal: Front Physiol Date: 2022-01-26 Impact factor: 4.755
Authors: Natalie Hunt; Christopher Rao; Robert Logan; Vishnu Chandrabalan; Jane Oakey; Claire Ainsworth; Neil Smith; Saswata Banerjee; Martin Myers Journal: BMJ Open Date: 2022-04-13 Impact factor: 3.006
Authors: Jayne Digby; Shirley Cleary; Lynne Gray; Pooja Datt; David R Goudie; Robert J C Steele; Judith A Strachan; Adam Humphries; Callum G Fraser; Craig Mowat Journal: United European Gastroenterol J Date: 2020-03-16 Impact factor: 4.623